AB
ACRS icon

Amalgamated Bank’s Aclaris Therapeutics ACRS Stock Holding History

Amalgamated Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,883
Closed -$9K – 1634
2025
Q4 		$9K Sell
2,883
-217
-7% -$548 ﹤0.01% 2447
2025
Q3 		$6K Hold
3,100
– – ﹤0.01% 2649
2025
Q2 		$4K Buy
+3,100
New +$4.2K ﹤0.01% 2810
2024
Q2 		– Sell
-2,307
Closed -$3K – 3004
2024
Q1 		$3K Sell
2,307
-7,491
-76% -$8.93K ﹤0.01% 2807
2023
Q4 		$10K Sell
9,798
-686
-7% -$2.09K ﹤0.01% 2852
2023
Q3 		$72K Hold
10,484
– – ﹤0.01% 2108
2023
Q2 		$109K Buy
10,484
+1,386
+15% +$12.5K ﹤0.01% 2029
2023
Q1 		$74K Sell
9,098
-1,355
-13% -$17.2K ﹤0.01% 2155
2022
Q4 		$165K Hold
10,453
– – ﹤0.01% 1928
2022
Q3 		$165K Buy
10,453
+1,001
+11% +$15.8K ﹤0.01% 1920
2022
Q2 		$132K Buy
9,452
+1,146
+14% +$16.1K ﹤0.01% 2057
2022
Q1 		$143K Buy
+8,306
New +$113K ﹤0.01% 2062

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Amalgamated Bank's ACRS Position: Q1 2026 in Review

Amalgamated Bank sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 2,883 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in ACRS in Q1 2022 and held it in 12 quarters. The position peaked at $165K in Q4 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Amalgamated Bank reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,883 Aclaris Therapeutics shares in Q1 2026, an estimated $9K.
  • Amalgamated Bank first reported a position in Aclaris Therapeutics in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Aclaris Therapeutics position peaked at $165K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.